A Three-Stage, Modified-Blind, Dose-Escalating Study to Assess Efficacy and Safety of Resiquimod Gel Applied 3 Times Per Week for 4 Weeks for the Treatment of Common Warts in Adults.
Phase of Trial: Phase II
Latest Information Update: 31 Jan 2012
At a glance
- Drugs Resiquimod (Primary)
- Indications Warts
- Focus Therapeutic Use
- Sponsors 3M Pharmaceuticals; Graceway Pharmaceuticals
- 31 Jan 2012 New trial record
- 16 Feb 2007 Company added as trial sponsor and additional lead trial centre identified as reported by ClinicalTrials.gov.